Idogen's CEO Anders Karlsson leaves for a new assignment and Christina Herder is appointed acting CEO
Idogen AB (publ) announces today that Anders Karlsson has decided to leave the company to move on to a CEO role in another Swedish biotechnology company. He will remain in his current position until 1 September 2022; the board is now starting a process to recruit a successor. Christina Herder, who has been a board member of the company for more than five years, has been appointed acting CEO while the recruitment of a new CEO is underway. She will retain her role on the board during this time. "It has been a privilege to lead Idogen for the past three years and I am convinced that the